These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8965118)

  • 1. A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data.
    Johnson KP
    J Neurol; 1996 Apr; 243(4 Suppl 1):S3-7. PubMed ID: 8965118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate (Copaxone).
    Francis DA
    Int J Clin Pract; 2001; 55(6):394-8. PubMed ID: 11501229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copolymer-1 in the treatment of multiple sclerosis.
    Boyden KM
    J Neurosci Nurs; 1998 Apr; 30(2):135-9; quiz 140-1. PubMed ID: 9642622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB
    Neurology; 1995 Jul; 45(7):1268-76. PubMed ID: 7617181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
    Ziemssen T; Neuhaus O; Hohlfeld R
    Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone).
    Johnson KP
    Mult Scler; 1996 Jul; 1(6):325-6. PubMed ID: 9345409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copolymer 1: from basic research to clinical application.
    Teitelbaum D; Arnon R; Sela M
    Cell Mol Life Sci; 1997 Jan; 53(1):24-8. PubMed ID: 9117994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glatiramer acetate in multiple sclerosis: a review.
    Ruggieri M; Avolio C; Livrea P; Trojano M
    CNS Drug Rev; 2007; 13(2):178-91. PubMed ID: 17627671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory vaccines against autoimmune diseases.
    Sela M
    Rejuvenation Res; 2006; 9(1):126-33. PubMed ID: 16608409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.
    Miller A; Shapiro S; Gershtein R; Kinarty A; Rawashdeh H; Honigman S; Lahat N
    J Neuroimmunol; 1998 Dec; 92(1-2):113-21. PubMed ID: 9916886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration.
    Flechter S; Kott E; Steiner-Birmanns B; Nisipeanu P; Korczyn AD
    Clin Neuropharmacol; 2002; 25(1):11-5. PubMed ID: 11852290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
    Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copolymer-1.
    Comi G; Moiola L
    Baillieres Clin Neurol; 1997 Oct; 6(3):495-509. PubMed ID: 10101586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific vaccines against autoimmune diseases.
    Sela M
    C R Acad Sci III; 1999 Nov; 322(11):933-8. PubMed ID: 10646086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.